Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers

NCT01447706 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.

NCT NCT01447706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01447706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Open Label Study of MM-121 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Platinum Resistant/ Refractory Advanced Ovarian Cancers
Lead sponsor
Merrimack Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
June 30, 2015
Enrollment
223 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer